Online inquiry

IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3738MR)

This product GTTS-WQ3738MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3738MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15370MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ13551MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ4503MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ5352MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ8119MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ11848MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ1298MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ6475MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW